Patient Educational
Resource
Download the DESTINY-Breast05 Guide for questions patients can ask their doctors.
DESTINY-Breast05
Clinical Trial Locator
About DESTINY-Breast05
DESTINY-Breast05 is evaluating safety and effectiveness of T-DXd in patients HER2-positive primary breast cancer whose tumors do not substantially shrink after neoadjuvant therapy and are at higher risk of having their cancer return. Additional treatment options are needed for these patients. This study examines the safety and effectiveness of fam-trastuzumab deruxtecan-nxki (T-DXd)* compared with trastuzumab emtansine (T-DM1).
The DESTINY-Breast05 Clinical Trial† is part of our continuing efforts to develop potentially new treatment options for patients with breast cancer. But advances in breast cancer treatment cannot happen without trial participants. We invite you to learn more about DESTINY-Breast05.
This website reflects investigational compounds and/or investigational uses of approved products. The safety and efficacy of these investigational agents or investigational uses of approved products has not been established. Any approved products should be used in accordance with their product labeling (or Prescribing Information).
*Known in the U.S. as fam-trastuzumab deruxtecan-nxki and formerly known as DS-8201a.
†The DESTINY-Breast05 Clinical Trial (DS8201-A-U305) is also known as NSABP B-60 in the United States and Canada, SOLTI2001 in Spain and Portugal, and GBG-103 and AGO-B-050 in Germany.
This website contains detailed medical information, but is intended
for both patients and healthcare professionals.